Author: Vitaliy Dadalyan

Celgene readies deal to buy Impact Biomedicines for as much as $7 billion – WSJ

Celgene Corp is expected to announce Monday that it is acquiring Impact Biomedicines for as much as $7 billion (£5.1 billion), the Wall Street Journal reported Sunday. Subsequent components of the deal would depend on approval from the Food and Drug Administration and successful acceptance in the market, according to the publication. Celgene and Impact Biomedicines did not immediately respond to requests for comment.


...Read the rest of this story